We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Roche Signs $1.7 Billion Deal With Blueprint Medicines for Precision Cancer Treatment
Roche Signs $1.7 Billion Deal With Blueprint Medicines for Precision Cancer Treatment
Roche has signed a $1.7 billion agreement with Blueprint Medicines to develop and commercialize Blueprint’s pralesetinib for treatment of patients with RET-altered cancers.